Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics

Merck KGaA is engaged in advanced discussions to acquire SpringWorks Therapeutics, a US-based biopharmaceutical company focused on rare diseases and cancer. The potential acquisition is valued at approximately $3.5 billion.

Deal Details

• The acquisition is expected to expand Merck’s portfolio in oncology and rare diseases.
• The deal’s announcement is anticipated to occur as early as next week.

Market Reaction

Merck’s stock price has increased by 2.93% to €121.25 in recent trading, indicating investor optimism about the potential acquisition.